药店对医保非医保患者采用“阴阳价格”，国家医保局出手整治

Core Insights - The National Healthcare Security Administration (NHSA) has issued a notice to address the issue of "dual pricing" in designated retail pharmacies, where prices for insured patients are higher than for non-insured patients [1][2][3] Group 1: Regulatory Actions - The NHSA has mandated local healthcare departments to monitor and address the "dual pricing" behavior in pharmacies, emphasizing that such practices violate agreements and harm insured patients [3] - Pharmacies found to be engaging in "dual pricing" may face serious consequences, including suspension of medical insurance settlements and potential legal actions [3] Group 2: Market Implications - The practice of "dual pricing" is seen as a form of price fraud that disrupts the pharmaceutical market and infringes on the rights of insured individuals [4] - Experts suggest that improving the efficiency of medical insurance settlements could alleviate financial pressures on pharmacies and reduce the occurrence of "dual pricing" [4][5] Group 3: Financial Considerations - The NHSA's notice highlights the need for pharmacies to conduct self-inspections and rectify discriminatory pricing practices promptly [3] - The implementation of an immediate settlement reform for basic medical insurance is expected to significantly reduce the accounts receivable issues faced by pharmacies, thereby enhancing their operational environment [4][5]